Technical Analysis for CSBR - Champions Oncology, Inc.
|Grade||Last Price||% Change||Price Change|
CSBR closed up 4.28 percent on Friday, January 18, 2019, on 71 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
|Weak or Absent||Up||Down||Up|
|See historical CSBR trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 18||MACD Bullish Centerline Cross||Bullish||0.00%|
|Jan 18||NR7||Range Contraction||0.00%|
|Jan 18||Multiple of Ten Bearish||Other||0.00%|
|Jan 18||Wide Bands||Range Expansion||0.00%|
|Jan 17||Wide Bands||Range Expansion||4.28%|
|Jan 16||Multiple of Ten Bearish||Other||5.60%|
|Jan 16||Outside Day||Range Expansion||5.60%|
|Jan 16||Wide Bands||Range Expansion||5.60%|
|Jan 15||Wide Bands||Range Expansion||1.94%|
|Jan 15||Overbought Stochastic||Strength||1.94%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assists physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. It also offers POS products, including personalized tumor boards that are designed to provide access to oncologists with expertise in particular tumor types; and gene sequencing that analyzes the genetic makeup of patient's tumor for the purpose of identifying useful drugs. In addition, the company offers Translational Oncology Solutions (TOS), including a preclinical Tumorgraft platform to pharmaceutical and biotechnology companies that uses vivo studies, which rely on implanting multiple tumors from TumorBank in mice and testing the therapy of interest on tumors. Further, it provides a bank of tumors that are acquired, collected, processed, validated, and stored for the use in TOS. The company markets its products through Internet, word of mouth, and a network of sales force. It serves patients, physicians, and drug development companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011 to reflect its new focus on developing technologies to personalize the development and use of oncology drugs. Champions Oncology, Inc. is headquartered in Hackensack, New Jersey.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more CSBR news...
|52 Week High||17.9|
|52 Week Low||3.045|
|200-Day Moving Average||8.5048|
|50-Day Moving Average||10.254|
|20-Day Moving Average||8.7025|
|10-Day Moving Average||9.61|
|Average True Range||0.7937|
|Chandelier Exit (Long, 3 ATRs )||7.9689|
|Chandelier Exit (Short, 3 ATRs )||9.2411|
|Upper Bollinger Band||10.6382|
|Lower Bollinger Band||6.7668|
|Percent B (%b)||0.83|
|MACD Signal Line||-0.2433|
|Market Cap||109.73 Million|
|Num Shares||11 Million|
|Price-to-Earnings (P/E) Ratio||-21.72|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||10.69|
|Resistance 3 (R3)||10.63||10.34||10.57|
|Resistance 2 (R2)||10.34||10.16||10.37||10.53|
|Resistance 1 (R1)||10.17||10.05||10.25||10.22||10.49|
|Support 1 (S1)||9.70||9.70||9.79||9.76||9.49|
|Support 2 (S2)||9.41||9.59||9.44||9.45|
|Support 3 (S3)||9.24||9.41||9.41|
|Support 4 (S4)||9.29|